Ascend Wellness Holdings resolved its dispute this week with MedMen over its buy of the corporate’s vertically built-in New York medical hashish license, Marijuana Business Daily stories. Underneath the phrases of the settlement, Ascend will buy 99.9% of MedMen’s New York operation for $88 million. That’s an extra $25 million on prime of the unique $63 million agreed to in December.
The deal contains MedMen’s develop facility in Utica and dispensaries in Manhattan, Lengthy Island, Syracuse, and Buffalo, the report says.
“We’re thrilled to place this dispute behind us and stay up for the upcoming closing of this transaction,” Ascend founder and CEO Abner Kurtin mentioned in a press launch.
At closing, Ascend pays $74 million and an extra $14 million, together with $10 million in payouts and one other $4 million associated to the settlement, when the primary adult-use gross sales are accomplished in a MedMen New York dispensary, the report says.
“Whereas we all the time search accretive offers, this transaction is especially engaging given a current comparable acquisition valued at $247 million,” Kurtin mentioned within the launch.
The settlement resolves a dispute between the 2 multi-state-operators the place MedMen claimed at one level that Ascend “exerted undue affect on New York State authorities officers as a way to receive regulatory approval” for the license acquisition, MedMen mentioned in its lawsuit. Particularly, the corporate had argued that Ascend’s donation to the workplace of New York Gov. Kathy Hochul (D) had spurred the acquisition’s approval, however MedMen ultimately dropped its lawsuit.
Get each day hashish enterprise information updates. Subscribe